Odyssey Therapeutics Reports Positive Phase 2a Data for OD-001 in Ulcerative Colitis, Secures Funding into H2 2028
ODTX sits 16% above its 52-week low of $16.
Summary
Odyssey Therapeutics reported positive clinical proof-of-concept data for its lead candidate, OD-001, in a Phase 2a trial for moderate to severe ulcerative colitis, with 27% of patients achieving clinical remission. This significant update follows the company's recent IPO in May 2026. The company also announced a strong pro-forma cash position of $464.4 million, which is expected to fund operations into the second half of 2028. This positive clinical data de-risks the lead program and provides a clear path forward for a key asset. The substantial cash runway offers significant financial stability, allowing for continued pipeline advancement. Investors will watch for the initiation of Phase 2b and combination trials for OD-001 in the second half of 2026, with results expected in the second half of 2027.
At the time of this announcement, ODTX was trading at $18.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $871.8M. The 52-week trading range was $16.00 to $18.72. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.